• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·HAPV3.SA
Share

Hapvida Participacoes e Investimentos S.A. Stocks

R$ 6.73Last Updated 14.08.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

R$ 1.01B

R$ 6.73
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hapvida Participações e Investimentos S.A., operating alongside its affiliated companies, is a key player in the Brazilian healthcare sector. The organization provides a variety of health and dental insurance plans. Its service offerings extend to direct medical and paramedical care, complemented by a suite of diagnostic services such as laboratory analysis, imaging, and ultrasound. Additionally, Hapvida supports educational initiatives by organizing courses, lectures, seminars, and similar events. The company is also involved in the administration, consultancy, deployment, and sale of individual, family, and collective healthcare systems and plans. It manages the reimbursement of medical, dental, hospital, and general healthcare expenses for its members, while simultaneously offering direct medical and hospital services. Hapvida maintains an extensive operational infrastructure, comprising 85 hospitals, 77 emergency units, 318 clinics, and 269 diagnostic centers. The company was founded in 1979 and is headquartered in Fortaleza, Brazil.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of HAPV3.SA is 14.6 and suggests 119% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.08.2026 21:00

Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16

16.08.2026 15:01

A Problem Worth Billions: How Much Is the EU Stock Market Losing Due to Mental Health Disorders?

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026